👤 Apurva Rautela

Phosphodiesterase 1B (PDE1B) and phosphodiesterase 10A (PDE10A), members of the phosphodiesterase superfamily, are responsible for cyclic nucleotide hydrolysis, thereby regulating key intracellular signaling pathways such as cAMP response element-binding protein (CREB) activation and brain-derived neurotrophic factor (BDNF) gene transcription. Both enzymes are predominantly expressed in the brain and co-localize with dopamine receptors, positioning them as potential targets for addressing schizophrenia, a disorder characterized by dopamine system dysfunction. PDE1B inhibition enhances D1-receptor signaling, ameliorating negative symptoms and cognitive deficits, while PDE10A inhibition modulates D2-receptor activity, potentially alleviating positive symptoms. Together, these mechanisms suggest that targeting PDE1B and PDE10A could offer an innovative avenue for the comprehensive management of schizophrenia. Recent advancements in structural and synthetic methodologies have significantly facilitated the design of small-molecule PDE1B and PDE10A inhibitors. Among these, ITI-214 (PDE1 inhibitors) and MK-8189 and EVP-6308 (PDE10A inhibitors) have proceeded to clinical trials, demonstrating promising therapeutic agents. Furthermore, dual PDE1B/10A inhibitors remain underexplored, with only compound 2 undergoing limited preclinical evaluation for its pharmacological efficacy and safety. Studies published between 2014 and 2025 were retrieved from the PubMed, Web of Science, and Scopus databases, highlighting advances in PDE1B and PDE10A inhibitors. This review provides a detailed overview of the structural and synthetic strategies employed in developing PDE1B, PDE10A, and dual PDE1/10 inhibitors, with a focus on their binding sites and structure-activity relationships (SARs). By addressing the limitations of current candidates and emphasizing the need for dual inhibitors, this review aims to guide future research efforts toward the discovery of more selective, potent, and clinically viable PDE1B and PDE10A inhibitors for schizophrenia. Show less

Neonatal sepsis is a significant cause of mortality in children under 5 years of age globally, with the highest incidence reported in India. The challenges in diagnosing neonatal sepsis often result in the irrational use of antibiotics. The aim of the study was to determine the diagnostic efficacy of interleukin 27 (IL-27) as a novel biomarker for the early diagnosis of neonatal sepsis. This prospective cohort study was conducted at a tertiary care hospital in North India from May 2019 to April 2020. Eighty neonates suspected of sepsis were enrolled based on the sepsis screen criteria approved by the National Neonatal Forum of India. Blood samples were collected for culture and biomarker analysis, with C-reactive protein (CRP), procalcitonin (PCT), and IL-27 levels measured. The diagnostic performance of IL-27 was compared to that of CRP and PCT. Out of 80 neonates, 56% were male and 44% were female. Blood cultures were positive in 51.2% of cases. The most common pathogens isolated were Gram-negative bacteria (41%), fungi (34%), and Gram-positive bacteria (25%). IL-27 demonstrated a sensitivity of 78.05%, specificity of 61.54%, positive predictive value of 68.09%, and negative predictive value (NPV) of 72.73%. In comparison, PCT showed the highest sensitivity (82.93%), and CRP had the highest specificity (79.49%). IL-27 levels were notably higher in blood culture-positive cases. IL-27 is a promising biomarker for the early diagnosis of neonatal sepsis, showing comparable sensitivity and NPV to PCT, but with lower specificity than CRP. Show less